http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101239964-B

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0299e256f5589776d4bd724070719e5b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_892c33e4735b1781cb423ea035722efc
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D311-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
filingDate 2008-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2012-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4717761eac03ccc430cca023fbdae4b1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e61d4ed2a146119acfd43ed26e29580e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25101115d9536c6a9dcf7c3af4db8b99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc7dbbad8562f90fa7a740ac2daac771
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e250923415b006334575c0d70715e5cd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_635ab7e939dc50ab15631addd6b05638
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3be4cbabf0db981fcae32d080277d4d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b64a71f8e695ede0780febd5fa06175
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_571fb4898ad405df13ef76edbae7ea35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63ed09d41d34d78f9c9c2c60543e2b5a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf0a9016700268f3d34a0927ae7cdcaa
publicationDate 2012-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-101239964-B
titleOfInvention 15-oxospiramilactone and its medicament composition, preparation method and application
abstract Provided is 15-oxospiramilactone compounds represented by formula (I), which are used as antineoplastic compositions with active agent. The compounds and compositions thereof can overcome drug resistance of tumour cells due to loss of Bax, overcome resistance of tumour cells to chemotherapy medicine due to Bc1-2 high expression, and induce apoptosis of the Bc1-2 high expression cells; the compounds and compositions thereof also can induce apoptosis of mouse embryo epithelium free of Bax and Bak; restrain growth of HCT116 Bax-/- replant nude Mouse tumor, and display that 15-oxo spiraea lactone can be used as chemotherapy medicine and has no obvious damage on animal when killing tumour cells with resistance to a plurality of chemotherapy medicine.
priorityDate 2008-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468104291
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467887368

Total number of triples: 26.